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Abstract 
Small molecules are pharmacological tools of considerable value in dissecting 
complex biological processes and identifying potential therapeutic interventions. 
Recently, the cellular quality control process of mitophagy attracted considerable 
research interest, however, the limited availability of suitable chemical probes 
restricted our understanding of the molecular mechanisms involved.  
Current approaches to initiate mitophagy include acute dissipation of the 
mitochondrial membrane potential (ΔΨm) by mitochondrial uncouplers (e.g. 
FCCP/CCCP), or the use of Antimycin A/Oligomycin to impair respiration. Both 
approaches impair mitochondrial homeostasis, and therefore limit the scope for 
dissection of subtle, bio-energy related regulatory phenomena.  
Recently, novel mitophagy activators acting independently of the respiration collapse 
have been reported, offering new opportunities to understand the process and 
potential for therapeutic exploitation.  
We have therefore summarized the current status of mitophagy modulators and 
analyzed the available chemical tools, commenting on their advantages, limitations 
and current applications. 
 
 
Key words: mitophagy, FCCP, SIRT1, p53, Nrf2, PMI
 2 
Introduction 
Mitochondrial autophagy, known as mitophagy, governs the elimination of 
dysfunctional or superfluous mitochondria and is therefore fundamental to both 
mitochondrial and cellular homeostasis.1 Impaired mitophagy may lead to an 
accumulation of damaged organelles within cells, underlying the pathogenesis of a 
number of chronic conditions including cancer, cardiovascular and liver diseases and 
neurodegeneration, particularly Parkinson’s disease (PD).2 
Mitophagy operates via a number of distinct but interconnected mechanisms that can 
be generally classified as ubiquitin (Ub) dependent and independent pathways.3 Ub-
driven mitophagy relies on the ubiquitination of mitochondrial surface proteins for the 
recognition of damaged organelles by the autophagic machinery. The PINK1-Parkin 
pathway for activation and execution of the process is currently the most studied 
mechanism of mitochondrial priming (Figure 1b). Dissipation of the mitochondrial 
membrane potential (ΔΨm) leads to the stabilization of the Ser/Thr kinase PINK1 
(PTEN induced putative kinase 1), thus facilitating its accumulation on the outer 
mitochondrial membrane (OMM).4 PINK1 activates the E3 Ub ligase Parkin via 
mechanism involving the phosphorylation of both Parkin and its substrate Ub at 
Ser65.5,6 Once localized on mitochondria, Parkin acts in concert with PINK1 to amplify 
the initial signal by decorating mitochondria with Ub chains, which are sequentially 
phosphorylated by PINK1 (Figure 1c).6 Besides Parkin, other Ub ligases, such as 
SMURF17 and Gp788, have been reported to contribute to the mitochondrial priming. 
The accumulation of pSer65-Ub chains on the OMM triggers the recruitment of the 
autophagy receptors optineurin (OPTN) and nuclear dot protein 52 (NDP52), which 
promote the biogenesis of phagophores in close proximity to mitochondria by 
recruiting the autophagy-initiating factors ULK1 (unc-51 like autophagy activating 
kinase 1), DFCP1 (Double FYVE-domain containing protein 1) and WIPI1 (WD 
repeat domain, phosphoinositide interacting 1).6 Moreover, OPTN and NDP52 act as 
molecular adaptors anchoring Ub-labelled mitochondria into autophagosomes by 
interacting directly with LC3 through their LC3-interacting regions (LIR) (Figure1b, 
c).  
In addition to Ub-driven mitophagy, the OMM-localized mitophagy receptors BNIP3 
(BCL2/adenovirus E1B 19 kDa protein-interacting protein 3),10 NIX1/BNIP3L,9 and 
FUNDC1 (FUN14 domain containing 1)11 target mitochondria to autophagosomes 
independently of mitochondrial ubiquitination by interacting directly with LC3 and 
GABARAP (GABAA receptor associated protein) through typical or atypical LIR motifs 
(Figure 2a). NIX1 was originally identified as a key mediator of mitochondrial 
 3 
removal during erythrocyte maturation,12 but recently shown to be involved in ΔΨm 
loss-induced mitophagy.9  
The expression of both NIX1 and the related BNIP3 is partially under the control of 
HIF-1 (hypoxia-inducible factor 1) and their up-regulation during hypoxia promotes 
the clearance of damaged mitochondria.14,15 BNIP3 along with FUNDC-1 are 
considered the main mediators of hypoxia-induced mitophagy.11,14 In contrast to NIX1 
and BNIP3, the expression of FUNDC1 is not altered significantly during hypoxic or 
mitochondrial depolarization events, but instead its activity relies heavily on post-
translational modifications.16 Under basal conditions, the interaction between LC3 
and FUNDC1 is suppressed by the phosphorylation of the latter at multiple sites that 
are located close to its LIR domain. Upon hypoxia or ΔΨm collapse however, the 
dephosphorylation of FUNDC1 at Ser13 by the Ser/Thr phosphatase PGAM5 
(Phosphoglycerate mutase family member 5) enhances its binding affinity for LC3 
and facilitates the anchoring of mitochondria into autophagosomes (Figure 2b).17 
Notably, the progress in understanding the molecular hierarchy governing mitophagy 
achieved with the aid of only a limited number of chemical tools. In particular, the 
conventional approach to trigger mitophagy in vitro resides in the chemically-induced 
collapse of ΔΨm and subsequent stabilization of PINK1. The vast majority of 
mitophagy inducers identified to date are in essence mitochondrial toxins that initiate 
a mitophagic response by inhibiting mitochondrial respiration. Despite their limitations 
and plethora of off-target effects, such agents are widely used in regulatory and 
mechanistic cell biology studies due to the lack of more suitable chemical tools.  
There is therefore a need to devise novel pharmacological approaches to manipulate 
the process and develop agents to activate mitophagy without perturbing the 
organelle as dramatically as most current inducers do. Besides their potential 
therapeutic utility in conditions associated with mitophagy defects, such agents would 
also serve as invaluable chemical probes to corroborate the core pathways of the 
process and unveil regulatory mechanisms and events that occur independently from 
the respiratory collapse. To delineate the current state of the field and highlight 
recent advances, we provide a critical appraisal of the chemical tools currently used 
to modulate mitophagy in addition to focusing on the most recent and promising 
approaches that pave the way for a better understanding of the process and leave 
hope for its future therapeutic exploitation. 
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H+ Ionophores  
Amongst the inducers of mitophagy identified to date, proton (H+) ionophores, 
hereafter referred to as protonophores, are employed widely in cell biology studies. 
Protonophores are weakly acidic lipophilic compounds capable of transporting H+ 
across the inner mitochondrial membrane (IMM), thereby depleting the 
electrochemical proton gradient and uncoupling oxidative phosphorylation from the 
electron transport chain (ETC).18 As a result of the extensive H+ leak mediated by 
such agents, mitochondria are targeted for degradation, while the rate of oxygen 
consumption is increased in an effort to restore the diminished ATP generation, 
making protonophores valuable tools for the study of both mitochondrial autophagy 
and bioenergetics. 
The phenylhydrazones carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and 
carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone (FCCP) and to a lesser extent 
the 2,4-dinitrophenol (DNP) have been extensively employed to probe the underlying 
mechanisms of mitophagy and characterize the biological pathways involved in this 
process (Table 1).6,19–21 CCCP in particular was one of the first agents reported to 
induce mitophagy and was successfully applied to unveil the involvement of the PD-
associated protein Parkin in the regulation of this process.20  
Despite their widespread use, protonophores have several limitations as mitophagy-
stimulating chemical probes (Figure 1a). In particular, their effects on mitochondria 
do not resemble naturally occurring conditions, being largely detrimental and leading 
eventually to mitochondrial failure.22 Furthermore, they affect the entire mitochondrial 
population rather than a specific subgroup and can even lead to the complete 
elimination of mitochondria from cells after longer treatments.20 Moreover, traditional 
protonophores are not specific for mitochondria and have protonophoric activity on 
other membranes, particularly the plasma membrane.23 As a result, they mediate a 
variety of off-target effects, including disruption of the microtubule cytoskeleton24, 
inhibition of lysosomal activity25 and activation of ion channels,26 which leads to 
relatively high levels of toxicity and a narrow therapeutic window. Notably, FCCP is 
cytotoxic, even at concentrations that are not high enough to dissipate ΔΨm and thus 
induce mitophagy.27  
Recently, a second generation protonophore, which is equally potent but less 
cytotoxic than FCCP, was reported.28 This novel compound, named BAM15, can 
enhance the rate of mitochondrial respiration in both cells and isolated mitochondria 
and exert protective effects against renal ischemia-reperfusion damage in vivo. In 
 5 
contrast to FCCP, BAM15 exhibits high selectivity for the IMM and does not 
depolarize the plasma membrane or cause mitochondrial failure at high 
concentrations. However, its mitophagy-inducing potential is not fully evaluated yet 
and further work is therefore required to assess its suitability in this context. 
Mitochondrial toxins 
Similarly to protonophores, various toxins and respiration inhibitors activate PINK1-
mediated mitophagy following dissipation of the ΔΨm (Figure 1a). A representative 
example is valinomycin, a highly specific potassium (K+) ionophore that owing to its 
high lipophilicity, is able to transport K+ ions across the IMM by masking their charge 
through a reversible interaction (Table 1).29 The resulting accumulation of K+ inside 
the mitochondrion eliminates the electrical potential and activates the PINK1-Parkin 
pathway without altering the pH gradient (Figure 1a, b). 
In addition to valinomycin, the ionophore salinomycin has been reported to induce 
mitophagy by interfering with mitochondrial K+ homeostasis (Table 1).30 However, its 
mode of action is distinct to that of valinomycin and instead of depolarizing the IMM, 
salinomycin induces its transient hyperpolarization.30,31 In contrast to valinomycin, 
salinomycin increases the efflux of K+ from the mitochondrion by catalyzing their 
electroneutral exchange against protons and subsequently modifies the pH gradient 
across the IMM.31 The acidification of the mitochondrial matrix impairs mitochondrial 
respiration and thus, limits the generation of ATP, eventually leading to mitochondrial 
failure and activation of the mitochondrial removal process.30,31  
Another example is the antibiotic antimycin A that elicits a mitochondria-targeted 
autophagic response by inhibiting the respiratory complex III and leading to 
increased levels of reactive oxygen species (ROS) (Table 1).32 Compared to 
protonophores and other mitochondrial toxins, antimycin A causes a relatively limited 
decrease in ΔΨm that is rapidly balanced by the reverse hydrolysis activity of the 
F1Fo-ATPsynthase.33 For that reason, it is often used in combination with oligomycin 
(Table 1), which prevents this compensatory mechanism by inhibiting the F1Fo-
ATPsynthase and thus facilitates a more intense depolarization.6 The activation of 
mitophagy by antimycin A and oligomycin is generally considered more relevant to 
naturally-occurring conditions, since both inhibitors are relatively selective for their 
targets and mediate fewer toxic effects, resulting in subtler mitochondrial damage.6,29  
Similarly to antimycin A, a diverse range of chemicals, including sodium selenite, 
diquat, retigeric acid B and paraquat have been reported to trigger mitophagy in 
response to elevated levels of oxidative stress (Table 1).4,20,35–37 Of particular interest 
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is sodium selenite, which induces a lethal form of mitophagy in human glioma cells, 
but not astrocytes.36 Mechanistically, sodium selenite appears to stimulate mitophagy 
by promoting a ROS-dependent activation of the E3 ubiquitin ligase MUL1 
(mitochondrial E3 ubiquitin protein ligase 1), which in turn recruits ULK1 (Unc-51 Like 
Autophagy Activating Kinase 1) to mitochondria, thus facilitating their autophagic 
degradation.38 More recently, it was shown to up-regulate the expression of ceramide 
synthase 1, which controls the biosynthesis of the sphingolipid C18-ceramide that in 
turn promotes lethal mitophagy by inhibiting mitochondrial respiration and recruiting 
LC3 via a direct interaction.39  
Parkinsonian toxins 
The pesticide paraquat, which is another well-studied mitochondrial toxin, activates 
mitophagy via excessive complex I-dependent superoxide generation.4,20 Similarly to 
other toxins, paraquat-induced mitophagy is initiated by mitochondrial depolarization 
and operates via the PINK1-Parkin pathway. Paraquat belongs to a group of 
neurotoxins, which are known to induce parkinsonian symptoms and are often used 
to model Parkinson’s disease both in vitro and in vivo.  
Like paraquat, other parkinsonian toxins, including rotenone, MPP+ (1-methyl-4-
phenylpyridinium) –the metabolically active form of MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine)– and 6-OHDA (6-hydroxyldopamine) stimulate mitophagy, 
although by a different mode of action (Table 1).40–42 Rotenone in particular causes a 
relatively mild mitochondrial depolarization, which is inadequate to induce PINK1-
mediated mitophagy in primary neurons or neuroblastoma cells.41 Rotenone, as well 
as 6-OHDA (and so does Staurosporine) activate the process by promoting the 
externalization of cardiolipin, which recruits the autophagic machinery via a direct 
interaction with LC3 (Figure 2c). Moreover, 6-OHDA and MPP+ were both found to 
promote the phosphorylation and mitochondrial accumulation of ERK2 (extracellular 
signal-regulated protein kinase 2), an event that drives mitochondria into 
autophagosomes and facilitates their degradation.40,43  
The identification of divergent mitophagic pathways in neurons, which are exploited 
by the parkinsonian toxins and others, such as the apoptotic agent Staurosporin, 
suggest that the PINK1-Parkin pathway might be not the primary mechanism of 
neuronal mitochondrial quality control.41 In fact, neurons exhibit a poor response to 
FCCP/CCCP-induced dissipation of ΔΨm compared to HeLa and other non-neuronal 
cell lines, as evidenced by the delayed translocation of Parkin.44 Parkinsonian toxins 
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may therefore represent preferential chemical tools to stimulate mitophagy in 
neurons and investigate the underlying regulatory mechanisms. 
Modulators of PINK1-Parkin activity  
Ample evidence from the literature suggests that the integrity of the PINK1-Parkin 
pathway is essential for mitochondrial recycling and function.45 Mutations in PINK1 
and Parkin that affect their catalytic activities can lead to impaired mitophagy and 
underlie rare forms of early-onset PD. Despite the recent advances and scientific 
excitement around this pathway, efforts to pharmacologically modulate it remain 
limited.  
An unconventional but promising strategy to enhance PINK1-mediated mitophagy is 
based on the identification of N6-furfuryl ATP (kinetin triphosphate, KTP) as a neo-
substrate that exhibits higher affinity for PINK1 compared to the native substrate, 
ATP (Figure 3a).46 KTP was shown to augment the kinase activity of both PINK1wt 
and PINK1G309D, a Parkinson’s disease-associated mutant with severely impaired 
kinase activity. Interestingly, kinetin (N6-furfuryl adenine), a cell permeable precursor 
of KTP, was able to enhance the PINK1-mediated phosphorylation of Parkin, 
accelerating its mitochondrial recruitment and the subsequent initiation of mitophagy 
after CCCP-induced mitochondrial insult (Table 1).46 Although still at an early stage, 
preliminary results suggest that this approach has great potential to restore 
mitophagy in conditions associated with loss-of-function PINK1 mutations. However, 
kinetin does not affect the stabilization of PINK1 under resting conditions and thus, 
an external stimulus, such as CCCP, is required to initiate mitophagy, which restricts 
its application as a mitophagy-stimulating chemical tool. 
An alternative and rather interesting approach to augment the activity of the PINK1-
Parkin pathway resides in the inhibition of the tumor suppressor p53, which regulates 
the expression levels of PARK2.47 On the other hand, Parkin represses the 
transcription of p53 by physically interacting with its promoter region48,49 – although 
this appears to depend on cell or tissue type.47 This suggests that at least in some 
particular cell types a feedback loop between Parkin and p53 exists that may play a 
regulatory role in mitophagy. In support of this notion, p53 may suppress mitophagy 
by directly interacting with Parkin and halting its translocation to mitochondria, whilst 
pharmacological intervention with pifithrin-α, a small molecule inhibitor of p53, 
restored mitochondrial clearance in a p53-dependent manner (Figure 3b).50 In a 
different study, pifithrin-α was shown to promote mitophagy and ameliorate 
mitochondrial dysfunction in type I and II mouse models of diabetes.51  
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Interestingly, elevated levels of p53 exist in the brains of animal models and human 
cases of PD, a condition strongly associated with impaired mitochondrial function and 
quality control,52,53 while inhibition of p53 by pifithrin-α reduces dopaminergic neuron 
death and protects against MPTP neurotoxicity in vivo.54 Moreover, p53-/- mice have 
higher levels of basal mitophagy compared to their wild type counterparts, leading to 
increased resistance against doxorubicin-induced mitochondrial injury.50 However, 
p53 is a master regulator of several cellular processes and as a result, its 
pharmacological targeting may impinge diverse biological effects beyond the 
induction of mitophagy. Therefore, despite the emerging link between p53 and 
Parkin-mediated mitophagy, the specificity in targeting mitophagy via this approach is 
questionable.  
In addition to p53 inhibitors, a diverse group of small molecule modulators of PARK2 
transcription was recently identified through high-throughput screening (HTS) of 
bioactive compounds using a Firefly/NanoLuc luciferase coincidence reporter 
system.55 These include modulators of epigenetic mechanisms, such as histone 
deacetylase and bromodomain inhibitors, and small molecule inhibitors of cholesterol 
biosynthesis, such as mevastatin and fluvastatin.56 Interestingly, the JNK inhibitor 
SR3306, another promising lead identified in the same study, seems to enhance 
mitochondrial quality control in a cell-based model of mitochondrial stress induced by 
the accumulation of misfolded ΔOTC (truncated ornithine transcarbamylase).  
Recently, novel molecular routes to enhance PINK1-Parkin mitophagy without 
interfering directly with the pathway were described. A good example is the 18-kDa 
translocator protein (TSPO), which regulates mitophagy downstream of the PINK1-
Parkin pathway via a ROS-sensitive mechanism.21 In particular, TSPO blocks 
mitophagy following FCCP-induced mitochondrial insult by inhibiting mitochondrial 
ubiquitination, but not PINK1 stabilization or Parkin translocation. TSPO levels are 
elevated in pathological conditions associated with mitophagy defects, highlighting its 
pharmacological targeting as a suitable strategy to therapeutically activate 
mitophagy.56 Though, the limited selectivity of the most widely used TSPO ligands 
may restrict the options for its targeting in this context,56,57 the recent elucidation of 
TSPOs three-dimensional structure shall facilitate the design of improved chemicals 
to shed light on the protein’s role in the modulation of mitophagy.56 
The ubiquitin specific peptidase 30 (USP30) is a mitochondrion-localized 
deubiquitylase known for its role in the regulation of mitochondrial morphology.58,59 
USP30 antagonizes Parkin-driven mitophagy by removing poly-ubiquitin chains from 
damaged mitochondria and thus stalling mitochondrial priming. USP30 knockdown is 
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sufficient to restore mitophagy in neuronal cells expressing a dysfunctional Parkin 
mutant and rescue motor function and mitochondrial defects in fly models of PD 
devoid of a fully functional Pink1-Parkin pathway. Despite the promising results 
obtained by the manipulation of USP30 expression levels, no pharmacological proof 
of concept is reported to date and the potential of USP30 inhibitors as mitophagy-
inducing molecules, such as the diterpenoid analogue 15-oxospiramilactone60, 
remains to be  elucidated.  
In addition to USP30, other deubiquitinating enzymes, including USP8 and USP15 
have recently been reported to oppose or even enhance Parkin-mediated 
mitochondrial priming.61 This is not surprising given the pivotal role of Ub signaling in 
the regulation of mitophagy. However, deubiquitylases have diverse biological 
functions62 and their pharmacological targeting by small molecule modulators could 
lead to non-specific events that are not directly related to the process of mitophagy 
thus limiting their use as mitophagy-stimulating chemical probes. 
Iron chelators 
The development of sensitive phenotypic assays for monitoring alterations in the 
levels of cellular mitophagy enabled the identification of several modulators of the 
process.63,64 In particular, a chemical screen utilizing a tandem mCherry-GFP tag 
anchored on the OMM, yielded the iron chelator deferiprone (DFP) as a novel 
inducer of mitophagy (Table 1 and Figure 5b).63 DFP was shown to promote 
mitochondrial turnover via an iron depletion-dependent mechanism without causing a 
ΔΨm collapse. Interestingly, DFP retains its activity in cells devoid of a fully functional 
PINK1-Parkin pathway and this has prompted its use as a chemical tool to assess 
Parkin-independent mitophagy in recent studies.65,66  
Intriguingly, 1,10’-phenanthroline (Phen), another compound with siderophore-like 
properties, was identified as a “hit” in a chemical screen for mitophagy activators 
(Table 1).64 In contrast to DFP, Phen mediates a collapse of ΔΨm, which is followed 
by a Drp1-dependent mitochondrial fragmentation and induction of mitophagy. 
Consistently with aspects of the latter study, Phen and the structurally distinct iron 
chelator, cicloprox olamine (Table 1), were reported to trigger mitophagy in response 
to mitochondrial depolarization in mammalian cells and nematodes.67 However, Phen 
is unable to exert similar effects in neuronal-like SH-SY5Y cells, suggesting that its 
mitophagic activity might be cell type dependent.68 In addition, the structurally similar 
siderophore 2’2-bipyridyl was shown to extend lifespan in C. elegans by inducing a 
mitophagic response that was dependent on PINK1 as well as PBR-1 and DCT-1, 
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the C. elegans homologues of Parkin and NIX1/BNIP3 respectively (Table 1 and 
Figure 5b).69  
Although pharmacologically induced iron depletion appears to stimulate mitophagy, 
further studies are required to elucidate the underlying mechanisms given the 
contradictory observations. With the exception of DFP, iron chelators trigger 
mitophagy by collapsing ΔΨm, which points towards mitochondrial toxicity. 
Nonetheless, a metabolic switch from oxidative phosphorylation to glycolysis is 
required for the induction of mitophagy by iron depletion,63 which may indicate 
respiratory injury and thus, restrict the therapeutic application of such agents 
particularly in neurodegenerative conditions, as neurons rely heavily on oxidative 
phosphorylation. 
SIRT1 activators 
Nicotinamide (NAM) was recently reported to promote mitophagy without perturbing 
mitochondrial function or collapsing the ΔΨm (Table 1).70 On the contrary, primary 
human fibroblasts treated with NAM exhibit elevated levels of resting ΔΨm – however 
this is accompanied by a fragmentation of the mitochondrial network.71 The effects of 
NAM are attributed to the activation of SIRT1 (silent information regulator T1), an 
NAD+-dependent deacetylase involved in the regulation of longevity.71 By acting as 
its biosynthetic precursor, NAM increases the cellular availability of NAD+, which in 
turn activates SIRT1 and promotes mitochondrial clearance. 
Interestingly, other SIRT1 activators, including the natural products resveratrol and 
fisetin and the synthetic small molecule SRT1720 (Table 1 and Figure 5b), reduce 
the mitochondrial network size to a similar extent as NAM, without increasing the 
ΔΨm, suggesting that the hyperpolarization induced by NAM is independent of its 
effects on SIRT1.71 Mechanistically, SIRT1 could trigger mitochondrial turnover by 
increasing the deacetylation and subsequent activation of LC372 or activating the 
mitophagy regulator UCP2 (uncoupling protein 2)73. Additionally, SIRT1 has a pivotal 
role in cellular adaptation to hypoxic conditions by interacting with, and deacetylating, 
FoxO3 (forkhead box O3).74 Activation of SIRT1 by calorie restriction up-regulates 
the FoxO3 downstream effector BNIP3 and promotes mitophagy in primary renal 
proximal tubular cells.75 In this regard, it would be interesting clarify whether the 
regulation of mitophagy by SIRT1 operates exclusively through a receptor-based 
mechanism implying that the functional integrity of the PINK1-Parkin pathway would 
not be required.  
 11 
In addition to NAD+ precursors and SIRT1 agonists, agents that can indirectly 
modulate the activity of SIRT1 by inhibiting NAD+-consuming enzymes, such as the 
poly(ADP-ribose) polymerase-1 (PARP-1), have the potential to stimulate mitophagy. 
A good example is AZD2281/olaparib (Table 1), a PARP-1 inhibitor that induces 
mitophagy in breast cancer cells and decreases the mitochondrial network size in a 
cell-based model associated with impaired mitophagy.73,76 Notably, hyperactivation of 
PARP-1 associates with impaired mitophagy and mitochondrial defects resulting from 
reduced NAD+ cellular content and increased SIRT1 activity.73 Genetic deletion or 
pharmacological inhibition of PARP-1 promotes an NAD+-mediated activation of 
SIRT1 that results in enhanced mitochondrial quality and respiration.77 Although the 
therapeutic effects of SIRT1 inducers in several in vivo disease models are well 
documented,78,79 triggering mitophagy using this approach raises the recurring issue 
of specificity given the crucial role of the deacetylase in the regulation of closely 
related processes, such as general autophagy80 and mitochondrial biogenesis.81 
Nrf2 inducers and the anterograde regulation of cell mitophagy 
The transcription factor nuclear factor E2-related factor 2 (Nrf2, Gene ID: 4780) has 
been proposed as an attractive target to enhance mitochondrial function and health. 
Genetic or pharmacological augmentation of Nrf2 activity has a number of beneficial 
effects on mitochondria.82 Nrf2 orchestrates the expression of a battery of 
cytoprotective genes harboring antioxidant response elements (AREs) in their 
promoter regions, amongst which of particular relevance to general and selective 
forms of autophagy are p62/SQSTM183 and NDP5284.  
Despite the emerging understanding of the crosstalk between Nrf2 and mitochondria, 
its role in mitophagy until recently was unexplored. We recently reported the 
identification of a small molecule that activates Nrf2 by disrupting its regulatory 
protein-protein interaction (PPI) with Keap1 (Kelch-Like ECH-Associated Protein 1),85 
a redox-sensitive protein that acts as an adaptor for the Cullin 3/Rbx1 ubiquitin ligase 
complex, facilitating the ubiquitination of Nrf2 and its subsequent proteasomal 
degradation (Figure 4).86 This compound, which we named p62/SQSTM1-mediated 
mitophagy inducer (PMI), increases the expression of p62/SQSTM1 and drives 
mitochondria into autophagy without disrupting the ΔΨm (Figure 5a).85 Nrf2 and 
p62/SQSTM1 are both indispensable to the mitophagic pathway exploited by PMI, as 
delivery of mitochondria to autophagosomes is abolished in Nrf2-/- or p62-/- cells. 
Interestingly, PMI is able to induce mitophagy in cells devoid of a fully functional 
PINK1-Parkin pathway (PINK1 KO or Parkin KD), which highlights its therapeutic 
potential in conditions associated with impaired PINK1 and Parkin activity. 
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Pharmacological activation of Nrf2 by PMI increments mitochondrial health as 
demonstrated by the elevated levels of resting ΔΨm in treated cells, which is 
consistent with the enhanced oxidative metabolism observed in Keap1-KO and 
Keap1-KD cells.87 Moreover, PMI does not alter mitochondrial morphology and in 
contrast to common mitophagy inducers, the activation of mitophagy is not 
accompanied by mitochondrial swelling or fragmentation.85 
PMI has a distinct mode of action compared to traditional Nrf2 inducers, such as the 
isothiocyanate sulforaphane (Figure 4).85,88 Typical Nrf2 activators are electrophiles 
that react with sensor cysteines on Keap1, inducing an irreversible conformational 
change that halts the ubiquitination of Nrf2.89 However, the vast majority of these 
compounds are capable of reacting with a range of cysteine-containing redox 
sensitive proteins, giving rise to a host of off-target effects.86 The activation of general 
autophagy by sulforaphane is an example of great relevance as it occurs via a ROS-
dependent mechanism and independently of its effects on Nrf2.90 On the other hand, 
PMI promotes a targeted autophagic degradation of mitochondria without affecting 
general autophagy.85 Notably, our preliminary results suggest that sulforaphane does 
not mediate similar effects on mitophagy, despite activating Nrf2 and up-regulating 
the expression of p62/SQSTM1. These differences further highlight the potential 
utility of PMI compared to sulforaphane and related electrophilic Nrf2 inducers and 
hint at the therapeutic potential of such compounds. 
Pharmacological inhibitors of mitophagy 
The most widely adopted protocol to block the process of mitophagy in vitro resides 
on the pharmacological inhibition of lysosomal acidification, using the V-ATPase 
(Vacuolar-type H+-ATPase) inhibitor bafilomycin A1 or the lysomotropic agents 
chloroquine and hydroxychloroquine (for a review see 91). In addition, compounds 
that suppress general autophagy by inhibiting the formation of autophagosomes have 
also been used to halt mitophagy, with the class III PI3K inhibitor 3-methyladenine 
being the most prominent example. Although these approaches are particularly 
effective at inhibiting mitophagy, they also affect other autophagic and lysosomal 
processes and are therefore largely unspecific.  
Novel strategies to inhibit mitophagy in a more specific manner have been described, 
however their application to date has been limited. In particular, peptide inhibitors of 
receptor-mediated mitophagy that are based on the LIR of FUNDC1 were recently 
reported.17 These include sequences that incorporate the Ser13 residue, whose 
phosphorylation status regulates the interaction of FUNDC1 with LC3 and thus its 
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ability to target mitochondria to autophagosomes. The LIR-mimetic peptide 
9QDYESDDDSYEVLDLTE25 was shown to disrupt the binding of the mitophagy 
receptor to LC3 with a Kd of 5.8 µM, which is 5-fold lower compared to that of the 
pSer13-containing analogue. Interestingly, conjugation of the unphosphorylated 
peptide inhibitor to a TAT-derived sequence yielded a cell-permeable probe that was 
able to suppress FCCP-induced mitophagy without affecting general autophagy, 
further supporting the potential of such molecules to modulate the process in a 
selective manner. 
A different approach to inhibit mitophagy is based on the suppression of 
mitochondrial fragmentation, an event that has been associated with mitophagy.92 
Compounds that inhibit the activity of Drp1 (dynamin-1-related protein) are capable of 
halting mitochondrial division and potentially prevent the initiation of mitophagy under 
conditions of mitochondrial stress. The mitochondrial division inhibitor (mdivi) is an 
allosteric modulator of Drp1 that was identified through a phenotypic screening 
exercise in yeast cells.93 Mdivi was shown to exert cardioprotective effects in vivo by 
blocking mitochondrial fission and at least in part by preventing abnormal 
mitophagy.94 A different example of a Drp1 modulator is the cell-permeable peptide 
P110, which consists of the highly conserved Drp1 region 110 (49DLLPRGT55) 
conjugated to a cell-permeating TAT peptide-derived sequence.95 Mechanistically, 
P110 appears to inhibit Drp1 by impairing its enzymatic activity and blocking its 
translocation to mitochondria by selectively disrupting its PPI with the OMM-localized 
protein Fis1. Interestingly, P110 does not inhibit mitochondrial fission under resting 
conditions, but instead prevents the abnormal mitochondrial fragmentation induced 
by several mitochondrial stressors, including FCCP and MPP+. However, to our 
knowledge no studies describing the effects of P110 on mitophagy have been 
reported to date and its potential as a negative modulator of the process remains to 
be determined. 
Concluding Remarks 
Restoring the ability of cells to efficiently eliminate damaged or dysfunctional 
mitochondria is likely to be pivotal to the prevention of a wide range of diseases. 
Equally paramount is the need to identify novel chemical probes that can be used to 
understand the process of mitophagy, and correct defects. Notably, the increased 
understanding of the molecular determinants governing mitophagy has not been 
mirrored by the development of suitable chemical probes with potential therapeutic 
uses.  
 14 
Both clinicians and scientists engaged in characterizing the mechanistic aspects of 
mitophagy will greatly benefit from improved pharmacological approaches to induce 
and control this mechanism of cellular quality control more selectively. From the 
recent literature it is notable that the original protocols based upon acute 
mitochondrial depolarization induced by non-specific agents (e.g. FCCP/CCCP), 
have been gradually refined into “milder” approaches (e.g. Antimycin A/Oligomycin) 
aimed at promoting mitophagy in a more physiologically compliant manner. Although 
uncoupling agents have been instrumental in understanding how depolarization of 
the mitochondrion triggers regulatory pathways leading to removal of the disposable 
organelles, the need for alternative approaches that are translatable into an in vivo 
context is now a priority.  
Specifically, the latest advancements in the field demonstrated that the process of 
mitophagy operates beyond the context of acute mitochondrial stress, such as during 
resting physiology, maintaining the integrity of the mitochondrial network and 
contributing to the preservation of cellular homeostasis. In particular, subtle changes 
in mitochondrial redox status96 such as increases mitochondrial respiratory activity 
and energy production97 were recently shown to activate mitophagy, adding another 
layer of complexity to the regulation of the process. Additionally, the accumulation of 
misfolded proteins can trigger PINK1-Parkin mediated mitophagy in energetically 
healthy mitochondria, suggesting that this pathway can also operate independently of 
respiratory collapse in response to other cues.98 Mitophagy is therefore likely to be 
part of a finely tuned mechanism that integrates both anabolic and catabolic 
mechanisms catalyzing the events of mitohormesis.99 
Triggering mitophagy through a pharmacologically-induced acute depolarization 
bears limitations, highlighting the need for alternative means to modulate the process 
and, eventually, exploit these for therapeutic purposes. The lack of mitophagy-
specific phenotypic assays that are suitable for High Throughput Screening (HTS), 
hampers the identification of novel chemical tools to manipulate the process. In 
addition, given the potential of several mitochondrial stressors to activate mitophagy, 
positive HTS “hits” are likely to be agents that may exert disruptive effects on the 
organelle and thus, have limited therapeutic potential. On the other hand, the 
increased understanding of the signaling pathways involved in the regulation of 
mitophagy, shall offer opportunities for targeted pharmacological interventions 
through the development of rationally designed chemical probes, as illustrated in 
recently reported successful examples.17 
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Agents that modulate cellular adaptive responses to stressors or toxins have the 
potential to further progress our understanding of the underpinning pathways of 
mitophagy. Notably, stimulation of mitophagy is proven to occur in response to the 
activation of Nrf2, a transcription factor often referred to as the master regulator of 
the antioxidant response.85 This highlights another scenario for mitophagy as a 
process integrated and governed by pathways dictating cellular resilience to impaired 
physiology, therefore widening the prospects for subsequent pharmacological 
validation and intervention in this process. 
We are therefore optimistic that the review of the pharmacological modulation of 
mitophagy provided here may draw attention to the need for new, specific modulators 
of mitophagy and facilitate discussion within the field about the best ways to identify 
and characterize the next generation of chemical probes and therapeutic agents that 
target this intriguing cellular process.  
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Legends to Figures 
Figure 1. PINK1/Parkin-mediated mitophagy 
The figure provides a schematic representation of the PINK1/Parkin pathway of 
mitophagy, activated by protonophores or mitochondrial toxins causing a collapse of 
the mitochondrial membrane potential (∆Ψm). Mitochondria collapsed in their ∆Ψm –
depicted in red here and the other figures- accumulate PINK1 on their surface 
triggering the recruitment of the Ubiquitin Ligase Parkin (a). The latter amplifies the 
mitophagy signal generated by PINK1 ubiquitinating mitochondrial proteins and 
thereby providing more ubiquitin substrate for PINK1 to phosphorylate (grey shapes). 
In this model, the mitophagy receptors NDP52 and OPTN, promote the recruitment of 
ULK1, which drives autophagosomes initiation on the surface of mitochondria being 
disposed –depicted in brown here and throughout the illustrations. NDP52 and 
OPTN, following accumulation of PINK1 can drive the process independently from 
the recruitment of Parkin (b).  
Figure 2. PINK1/Parkin-independent mechanisms of mitophagy 
Autophagic removal of mitochondria with collapsed ∆Ψm may occur also via 
mechanisms other than the PINK1/Parkin pathway as proven during hypoxia which 
impairs the respiration of mitochondria flagging these for disposal. Panels A and B 
report the pathways involved in this process with A depicting the key steps of the 
mitophagy process mediated by the accumulation of NIX1 or BNIP3 on mitochondria 
to be removed –represented in red- and B the one coordinated by PGAM5 and 
FUNDC1: all leading to recruitment of autophagosomes via LC3 on mitochondria 
undergoing mitophagy –depicted in brown. The same happens when Cardiolipin 
(green) as described in Panel C mediates mitophagy. The externalization of 
Cardiolipin on the mitochondrial surface triggers mitophagic response as it is 
demonstrated following inhibition of intracellular kinases via staurosporine or in 
presence of rotenone and 6-OHDA.   
Figure 3. Activation of Ub-dependent mitophagy by modulators of the PINK1-
Parkin pathway 
The PINK1/Parkin way of mitophagy can be exploited by pharmacological tools 
acting on specific steps of the pathway. One of these consists in boosting the actual 
kinase activity of the accumulated PINK1 on mitochondria with collapsed ∆Ψm -
depicted in red. Panel A reports specifically of kinetin (N-furfuryl adenine) which is a 
cell permeable precursor of the Kinetin Triphosphate (KTP): a neo-substrate for 
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PINK1 showing higher affinity compared to ATP. The increased KTP pools 
accelerate Parkin recruitment on mitochondria which already have their ∆Ψm 
collapsed -and therefore represented in red- subsequent initiation of mitophagy by 
improving the PINK1-mediated phosphorylation of Parkin. Panel B schematizes 
instead the pharmacological intervention with pifithrin-α, a small molecule inhibitor of 
p53, able to restore the clearance of mitochondria in a p53-dependent manner. 
Pifithrin-α operates exploiting the feedback loop between Parkin and p53 that 
regulates the expression levels of PARK2 improving the process overall as done by 
Kinetin. 
Figure 4. Chemical approaches to inhibit the Keap1-mediated degradation of 
Nrf2.  
Model reporting indirect (sulforaphane) and direct (PMI) pharmacological strategies 
to inhibit the Keap1-mediated degradation of Nrf2 leading to the nuclear 
accumulation of the latter and the subsequent transcriptional activation of genes 
involved in the regulation of both mitochondrial function and autophagy. One of these 
is the sequestosome P62/SQSTM1 via which the activation of mitophay by the direct 
approach of PMI occurs.  
Figure 5. The model of Mitophagy induction via PMI, SIRT1 activators and iron 
chelators 
Panel A reports the cartoon representation of the mitophagy induction by PMI. PMI 
exploits ubiquitination mechanisms currently ill-defined. This approach promotes the 
autophagosomal targeting of mitochondria and their disposal. However it does so by 
leaving their ∆Ψm intact. Mitochondria are therefore depicted in brown but never in 
red implying that they are primed for mitophagic disposal without this intermediate 
step common to many processes of mitophagy. Panel B summarizes the induction of 
mitophagy via SIRT-1 activators that operate by increasing the ∆Ψm of mitochondria, 
which are therefore represented with a shining tone of green (i). The same panel 
reports also on the iron chelators, which apparently involve more than one 
mechanism to complete the autophagic removal of mitochondria (ii). 
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Table 1. List of the pharmacological agents inducing cellular mitophagy. 
Pharmacological 
class 
Mitophagy 
inducer Chemical structure Mechanism Ref 
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Protonophores 
CCCP and 
FCCP 
 
Proton leak-induced 
loss of ΔΨm. 
4,19–21,86 
DNP 
 
100 
K+ ionophores 
Valinomycin 
 
ΔΨm collapse due to 
K+ influx. 
4,64 
Salinomycin 
 
K+/H+ antiporter 
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matrix acidification 
and mitochondrial 
failure. 
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 28 
Respiratory 
Complex III & 
ATP synthase 
inhibitor 
Antimycin A & 
Oligomycin 
 
Increased 
superoxide 
generation coupled 
with ΔΨm loss. 
6,64 
Superoxide 
generator Sodium selenite 
 
MUL1 activation & 
ceramide synthase 1 
up-regulation. 
37,40 
Apoptotic agent Retigeric acid B 
 
Mitochondrial 
damage and ΔΨm 
loss. 
38 
Parkinsonian 
toxins 
Diquat 
 Superoxide-induced 
mitochondrial 
damage. 
4,36 
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 29 
Rotenone 
 
ROS accumulation 
and mitochondrial 
damage: Cardiolipin-
dependent 
mitophagy. 
42 
MPP+ 
 
ROS accumulation 
and mitochondrial 
damage: ERK1/2-
dependent 
mitophagy. 
42,43 
6-OHDA 
 
ROS accumulation 
and mitochondrial 
damage: ERK1/2- 
and cardiolipin-
dependent 
mitophagy. 
41,42 
Pan-kinase 
inhibitor Staurosporin 
 
Mitochondrial 
damage and ΔΨm 
loss: activation of 
PINK1-Parkin 
pathway and 
cardiolipin-
dependent 
mitophagy. 
42 
Iron chelators 
Deferiprone 
(DFP) 
 
Iron chelation-
dependent and 
Parkin-independent 
mitophagy. 
64,66 
2’2-Bipyridyl 
 
Mitophagy 
dependent on 
PINK1, PDR-1 
(Parkin) and DCT-1 
(Nix). 
70 
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Mitochondrial 
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ΔΨm loss 68 
PINK1 enhancer 
Kinetin 
triphosphate, 
KTP 
 
Enhanced kinase 
activity of PINK1 
47 
p53 inhibitor Pifithrin-α 
 
Inhibition of p53 and 
possible activation of 
Parkin. 
51,52 
SIRT1 agonists 
Resveratrol 
 
Activation of SIRT1. 
72 
Fisetin 
 
69,72 
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 31 
NAD+ precursor Nicotinamide 
(NAM) 
 
NAD+ accumulation: 
activation of SIRT1. 
69,71,72 
PARP-1 inhibitor AZD2281 
(olaparib) 
 
NAD+ accumulation: 
activation of SIRT1. 
74,77 
Keap1 inhibitor PMI 
 
P62/SQSTM1- 
dependent 
mitophagy. 
85 
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